NIAID’s Division of Microbiology and Infectious Diseases (DMID) seeks a pool of contractors who can provide Vaccine (And Other Biologic) Manufacturing Services for Infectious Diseases. The solicitation’s purpose is to support manufacturing of material to advance preclinical, nonclinical, and Phase I/II clinical studies (e.g., vaccines, other biologics, vaccine components, and reagents). Thus, these services will provide preclinical development support for multiple vaccine and biologic candidates as needed.
NIAID anticipates awarding multiple Indefinite Delivery/Indefinite Quantity (IDIQ) contracts to organizations that best meet the overall qualifications needed to fulfill the technical requirements of this contract. Contractors may submit proposals for a single Task Area or multiple Task Areas, as listed below:
- Task Area A: Product Development Plans (PDPs) and Other Analyses
- Task Area B: Product Development & Manufacture of Non-GMP Material
- Task Area C: Bank Optimization and Master Banks
- Task Area D: Engineering and GMP Material
The contractor shall perform services that support countermeasures for the following:
- Diseases caused by pathogens and toxins on the NIAID Category A, B, and C Priority Pathogens list; refer to NIAID Emerging Infectious Diseases/Pathogens.
- Anti-microbial resistant and multi-drug resistant infections.
- Other infections.
- Fungal infections.
- Viral Infections.
- Parasitic diseases.
Details and Deadline Information
Through this solicitation, NIAID plans to award IDIQ contracts with a term of 10 years with cost reimbursement or firm fixed-price type task orders awarded from the parent contract to be fully funded for the base period beginning on or around May 1, 2025. The contractor shall be reimbursed by the government in an amount not less than a total of $10,000 (minimum) nor more than a total of $48,000,000 (maximum) for successful performance of this contract.
The deadline to submit an offer is May 17, 2024, by 2 p.m. local time.
Direct any related inquiries to NIAID’s primary point of contact, Andrew Cherry, at cherryan@niaid.nih.gov or 240-669-5138.